At the same time, the clinical phase I/II trials of barasertib in acute myeloid leukemia showed that the inhibition of CPC components had an encouraging improvement in the complete response (CR) rate compared with low-dose cytosine (LDAC), further supporting the feasibility of targeting ONECUT3 (57, 58). Here, ONECUT3 is linked to acute myeloid leukemia.